Word

ALLISON INSTITUTE

Status

Pending

Status Code

731

Status Date

Thursday, April 11, 2024

Serial Number

97975242

Mark Type

4000

Filing Date

Friday, March 25, 2022

Published for Opposition

Tuesday, February 21, 2023

Trademark Owner History

The Board of Regents of the University of Texas System - Owner At Publication

Classifications

36 Charitable fundraising services

35 Promoting collaboration within the scientific, research, pharmaceutical, and medical communities to achieve advances in healthcare, including to accelerate the development and use of immunotherapy in treatment of disease

45 Providing patient advocate services in the treatment of diseases and disorders utilizing immunotherapy

44 Medical services; Dispensing of pharmaceuticals; Medical and pharmaceutical consultation; Medical services relating to cancer; Dispensing of pharmaceuticals relating to cancer; immunobiology and immunotherapy medical services; medical services, namely, the treatment of cancer, disease management, disease prevention and early detection, standardized diagnosis, staging and treatment, care and care assessment, medical counseling; medical consulting services, namely, consulting on the treatment of cancer, disease management, disease prevention and early detection, standardized diagnosis, staging and treatment, care and care assessment, and patient care management; providing medical information; providing health information in the field of immunobiology, immunotherapy, oncology and diseases; providing a web site featuring medical information; providing a web site featuring health information in the field of immunobiology, immunotherapy, oncology and diseases; providing medical information, consultancy and advisory services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, medical diagnostic testing, monitoring and reporting services; providing information on health care via a telephone and the internet; providing information on cancer treatment; medical services, namely, treatment in the field of oncology and related health problems and diseases; providing medical information to patients and medical professionals in the field of immunotherapy and cancer treatment; medical analysis services, namely, analysis of tumors, cancer or equivalent medical conditions

42 Medical research services; medical research, development, technical design, testing, and analysis services in the field of immunobiology, immunotherapy, antibodies, and oncology; consulting services in the field of immunobiology, immunotherapy, antibodies, and oncology; medical research and development of antibodies, therapeutic products, vaccines, immunotherapy treatments and diagnostic products; medical research services in the field of immune repertoire analysis and the genome; scientific research in the fields of immunobiology, immunotherapy, antibodies and oncology; biological research; laboratory research services in the fields of immunobiology, immunotherapy, antibodies, oncology, and cellular engineering; medical laboratory services; providing information on medical and scientific research in the field of immunobiology and immunotherapy; medical and scientific research for others in the field of stem cell research, cancer, immunobiology and immunotherapy; compiling data for research purposes in the field of medical science and medical consultancy; medical and scientific research liaison services, namely, consulting in the field of scientific research pertaining to clinical trials in the fields of health care, medicine, immunobiology, immunotherapy, pharmacology and biotechnology; collection and management of medical and scientific data for research purposes in the field of medical and scientific research; Pharmaceutical research services; Pharmaceutical research services relating to cancer

"INSTITUTE"

Trademark Events

Apr 11, 2024

Sou Extension 2 Granted

Apr 11, 2024

Sou Extension 2 Filed

Apr 11, 2024

Sou Teas Extension Received

Oct 13, 2023

Notice Of Approval Of Extension Request E-Mailed

Oct 11, 2023

Sou Extension 1 Granted

Oct 11, 2023

Sou Extension 1 Filed

Oct 11, 2023

Sou Teas Extension Received

Apr 18, 2023

Noa E-Mailed - Sou Required From Applicant

Feb 21, 2023

Official Gazette Publication Confirmation E-Mailed

Feb 21, 2023

Published For Opposition

Feb 1, 2023

Notification Of Notice Of Publication E-Mailed

Jan 17, 2023

Approved For Pub - Principal Register

Jan 11, 2023

Examiner's Amendment Entered

Jan 11, 2023

Notification Of Examiners Amendment E-Mailed

Jan 11, 2023

Examiners Amendment E-Mailed

Jan 11, 2023

Examiners Amendment -Written

Dec 12, 2022

Divisional Processing Complete

Nov 1, 2022

Divisional Request Received

Dec 5, 2022

Case Assigned To Intent To Use Paralegal

Nov 1, 2022

Teas Request To Divide Received

Aug 29, 2022

Notification Of Non-Final Action E-Mailed

Aug 29, 2022

Non-Final Action E-Mailed

Aug 29, 2022

Non-Final Action Written

Aug 25, 2022

Assigned To Examiner

Mar 30, 2022

New Application Office Supplied Data Entered

Mar 29, 2022

New Application Entered